Ascendis Pharma A (ASND) Research & Development (2013 - 2026)

Ascendis Pharma A has reported Research & Development for 13 years, with the latest figure at -$69.1 million in Q1 2026.

• Quarterly Research & Development rose 24.12% year-over-year to -$69.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$156.8 million (up 5.94% YoY) and the FY2025 annual result came in at $353.4 million, up 7.73% from the prior year.
• Research & Development rose to -$69.1 million in Q1 2026 per ASND's latest filing, from -$91.0 million in the prior quarter.
• Over five years, Research & Development peaked at $121.3 million in Q3 2023 and troughed at -$91.1 million in Q1 2025.
• A 5-year average of $35.3 million and a median of $89.9 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 47.55% in 2022, then sank 218.63% in 2025.
• Over 5 years, Research & Development stood at $110.8 million in 2022, then declined by 11.76% to $97.8 million in 2023, then sank by 186.65% to -$84.7 million in 2024, then slipped by 7.36% to -$91.0 million in 2025, then rose by 24.01% to -$69.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered -$69.1 million, -$91.0 million, and -$78.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.